Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma
To compare the clinical efficacies and adverse reactions between transcatheter arterial chemoembolization (TACE), γ-ray 3-dimensional fractionated stereotactic conformal radiotherapy (FSCR), and TACE combined with FSCR for primary hepatocellular carcinoma.The study was approved by the Institutional...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2018-06, Vol.97 (22), p.e10890-e10890 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e10890 |
|---|---|
| container_issue | 22 |
| container_start_page | e10890 |
| container_title | Medicine (Baltimore) |
| container_volume | 97 |
| creator | Cai, Yeyu Chang, Qian Xiao, Enhua Shang, Quan-Liang Chen, Zhu |
| description | To compare the clinical efficacies and adverse reactions between transcatheter arterial chemoembolization (TACE), γ-ray 3-dimensional fractionated stereotactic conformal radiotherapy (FSCR), and TACE combined with FSCR for primary hepatocellular carcinoma.The study was approved by the Institutional Review Board, and informed consent was waived due to the retrospective study design. About 121 patients met the inclusion criteria and were included in this study, from March 2008 to January 2010, in the Second Xiangya Hospital. Forty-six patients underwent TACE alone, 36 patients underwent γ-knife alone, and 39 were treated by γ-knife combined with TACE. Short-term effects, overall survival rates, adverse reactions, and survival times were compared between the 3 treatment groups.Short-term effects were observed in 41.3% of the TACE group, 33.3% of the γ-knife group, and 64.1% of the TACE combined γ-knife group (P = .020). Overall survival rates at 6,12, 18, and 24 months were 50%, 34.8%, 28.3%, and 21.7% for the TACE group, 36.1%, 30.6%, 16.7%, and 11.1% for γ-knife group, and 84.6%, 71.8%, 61.5%, and 30.8% for TACE combined γ-knife group, respectively. The differences in the overall survival rates at 6, 12, and 18 months between the 3 groups were statistically significant (P = 0), but the overall survival rates at 24 months in the 3 groups were not significantly different (P = .117). The median survival time was 7 months for the TACE group, 3 months for the γ-knife group, and 20 months for the TACE combined γ-knife group (P = 0). There were statistically significant differences (P = .010) of leukopenia between the 3 groups, and no statistically significant differences of (P > .05) thrombocytopenia, anemia, nausea, vomiting, and liver function lesions.TACE combined with γ-knife for primary hepatocellular carcinoma is superior to TACE or γ-knife alone in short-term and long-term effects. This procedure is a mild, safe, and effective treatment for primary hepatocellular carcinoma. |
| doi_str_mv | 10.1097/MD.0000000000010890 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6392550</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>29851811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4179-f9a304050b1591846177959c853a93e36c0ee18b49bb1f8f536b01b5f0e751c3</originalsourceid><addsrcrecordid>eNpdkc1O3DAUha2qqExpnwAJedkuAnYcx_EGCQ30RwKxmb11bW6IwYlHToZR-wB9Id6DZ6qnQ_nzwpbOPee7kg8h-5wdcqbV0cXpIXs-nDWavSMzLkVdSF1X78mMsVIWSqtql3wcx5tsEqqsPpDdUjeSN5zPyJ9FgmF0MHU4YaKQ8u0hUNdhH7G3MfjfMPk40C-Lk_nZV-pib_2AV3Ttp44-3Be3g29xIy8hZXmKdGOkMT0PIcQBaZulDpcwRYchrAIk6iA5P8QePpGdFsKInx_fPbL4draY_yjOL7__nJ-cF67iShetBsEqJpnlUvOmqrlSWmrXSAFaoKgdQ-SNrbS1vG3a_BeWcStbhkpyJ_bI8Ra7XNkerxwOU4Jglsn3kH6ZCN68ngy-M9fxztRCl1KyDBBbgEtxHBO2T1nOzKYVc3Fq3raSUwcv1z5l_teQDdXWsI4hFzDehtUak-kQwtT940mly6JkvGF1hhZZEVr8BXrEmvY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Cai, Yeyu ; Chang, Qian ; Xiao, Enhua ; Shang, Quan-Liang ; Chen, Zhu</creator><creatorcontrib>Cai, Yeyu ; Chang, Qian ; Xiao, Enhua ; Shang, Quan-Liang ; Chen, Zhu</creatorcontrib><description>To compare the clinical efficacies and adverse reactions between transcatheter arterial chemoembolization (TACE), γ-ray 3-dimensional fractionated stereotactic conformal radiotherapy (FSCR), and TACE combined with FSCR for primary hepatocellular carcinoma.The study was approved by the Institutional Review Board, and informed consent was waived due to the retrospective study design. About 121 patients met the inclusion criteria and were included in this study, from March 2008 to January 2010, in the Second Xiangya Hospital. Forty-six patients underwent TACE alone, 36 patients underwent γ-knife alone, and 39 were treated by γ-knife combined with TACE. Short-term effects, overall survival rates, adverse reactions, and survival times were compared between the 3 treatment groups.Short-term effects were observed in 41.3% of the TACE group, 33.3% of the γ-knife group, and 64.1% of the TACE combined γ-knife group (P = .020). Overall survival rates at 6,12, 18, and 24 months were 50%, 34.8%, 28.3%, and 21.7% for the TACE group, 36.1%, 30.6%, 16.7%, and 11.1% for γ-knife group, and 84.6%, 71.8%, 61.5%, and 30.8% for TACE combined γ-knife group, respectively. The differences in the overall survival rates at 6, 12, and 18 months between the 3 groups were statistically significant (P = 0), but the overall survival rates at 24 months in the 3 groups were not significantly different (P = .117). The median survival time was 7 months for the TACE group, 3 months for the γ-knife group, and 20 months for the TACE combined γ-knife group (P = 0). There were statistically significant differences (P = .010) of leukopenia between the 3 groups, and no statistically significant differences of (P > .05) thrombocytopenia, anemia, nausea, vomiting, and liver function lesions.TACE combined with γ-knife for primary hepatocellular carcinoma is superior to TACE or γ-knife alone in short-term and long-term effects. This procedure is a mild, safe, and effective treatment for primary hepatocellular carcinoma.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000010890</identifier><identifier>PMID: 29851811</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - therapy ; Catheterization, Peripheral - methods ; Catheterization, Peripheral - mortality ; Chemoembolization, Therapeutic - methods ; Chemoembolization, Therapeutic - mortality ; Combined Modality Therapy ; Female ; Humans ; Liver Neoplasms - mortality ; Liver Neoplasms - therapy ; Male ; Middle Aged ; Observational Study ; Radiosurgery - methods ; Radiosurgery - mortality ; Radiotherapy, Conformal - methods ; Radiotherapy, Conformal - mortality ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Young Adult</subject><ispartof>Medicine (Baltimore), 2018-06, Vol.97 (22), p.e10890-e10890</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4179-f9a304050b1591846177959c853a93e36c0ee18b49bb1f8f536b01b5f0e751c3</citedby><cites>FETCH-LOGICAL-c4179-f9a304050b1591846177959c853a93e36c0ee18b49bb1f8f536b01b5f0e751c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392550/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392550/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29851811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cai, Yeyu</creatorcontrib><creatorcontrib>Chang, Qian</creatorcontrib><creatorcontrib>Xiao, Enhua</creatorcontrib><creatorcontrib>Shang, Quan-Liang</creatorcontrib><creatorcontrib>Chen, Zhu</creatorcontrib><title>Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>To compare the clinical efficacies and adverse reactions between transcatheter arterial chemoembolization (TACE), γ-ray 3-dimensional fractionated stereotactic conformal radiotherapy (FSCR), and TACE combined with FSCR for primary hepatocellular carcinoma.The study was approved by the Institutional Review Board, and informed consent was waived due to the retrospective study design. About 121 patients met the inclusion criteria and were included in this study, from March 2008 to January 2010, in the Second Xiangya Hospital. Forty-six patients underwent TACE alone, 36 patients underwent γ-knife alone, and 39 were treated by γ-knife combined with TACE. Short-term effects, overall survival rates, adverse reactions, and survival times were compared between the 3 treatment groups.Short-term effects were observed in 41.3% of the TACE group, 33.3% of the γ-knife group, and 64.1% of the TACE combined γ-knife group (P = .020). Overall survival rates at 6,12, 18, and 24 months were 50%, 34.8%, 28.3%, and 21.7% for the TACE group, 36.1%, 30.6%, 16.7%, and 11.1% for γ-knife group, and 84.6%, 71.8%, 61.5%, and 30.8% for TACE combined γ-knife group, respectively. The differences in the overall survival rates at 6, 12, and 18 months between the 3 groups were statistically significant (P = 0), but the overall survival rates at 24 months in the 3 groups were not significantly different (P = .117). The median survival time was 7 months for the TACE group, 3 months for the γ-knife group, and 20 months for the TACE combined γ-knife group (P = 0). There were statistically significant differences (P = .010) of leukopenia between the 3 groups, and no statistically significant differences of (P > .05) thrombocytopenia, anemia, nausea, vomiting, and liver function lesions.TACE combined with γ-knife for primary hepatocellular carcinoma is superior to TACE or γ-knife alone in short-term and long-term effects. This procedure is a mild, safe, and effective treatment for primary hepatocellular carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Catheterization, Peripheral - methods</subject><subject>Catheterization, Peripheral - mortality</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Chemoembolization, Therapeutic - mortality</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Observational Study</subject><subject>Radiosurgery - methods</subject><subject>Radiosurgery - mortality</subject><subject>Radiotherapy, Conformal - methods</subject><subject>Radiotherapy, Conformal - mortality</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1O3DAUha2qqExpnwAJedkuAnYcx_EGCQ30RwKxmb11bW6IwYlHToZR-wB9Id6DZ6qnQ_nzwpbOPee7kg8h-5wdcqbV0cXpIXs-nDWavSMzLkVdSF1X78mMsVIWSqtql3wcx5tsEqqsPpDdUjeSN5zPyJ9FgmF0MHU4YaKQ8u0hUNdhH7G3MfjfMPk40C-Lk_nZV-pib_2AV3Ttp44-3Be3g29xIy8hZXmKdGOkMT0PIcQBaZulDpcwRYchrAIk6iA5P8QePpGdFsKInx_fPbL4draY_yjOL7__nJ-cF67iShetBsEqJpnlUvOmqrlSWmrXSAFaoKgdQ-SNrbS1vG3a_BeWcStbhkpyJ_bI8Ra7XNkerxwOU4Jglsn3kH6ZCN68ngy-M9fxztRCl1KyDBBbgEtxHBO2T1nOzKYVc3Fq3raSUwcv1z5l_teQDdXWsI4hFzDehtUak-kQwtT940mly6JkvGF1hhZZEVr8BXrEmvY</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Cai, Yeyu</creator><creator>Chang, Qian</creator><creator>Xiao, Enhua</creator><creator>Shang, Quan-Liang</creator><creator>Chen, Zhu</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20180601</creationdate><title>Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma</title><author>Cai, Yeyu ; Chang, Qian ; Xiao, Enhua ; Shang, Quan-Liang ; Chen, Zhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4179-f9a304050b1591846177959c853a93e36c0ee18b49bb1f8f536b01b5f0e751c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Catheterization, Peripheral - methods</topic><topic>Catheterization, Peripheral - mortality</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Chemoembolization, Therapeutic - mortality</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Observational Study</topic><topic>Radiosurgery - methods</topic><topic>Radiosurgery - mortality</topic><topic>Radiotherapy, Conformal - methods</topic><topic>Radiotherapy, Conformal - mortality</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cai, Yeyu</creatorcontrib><creatorcontrib>Chang, Qian</creatorcontrib><creatorcontrib>Xiao, Enhua</creatorcontrib><creatorcontrib>Shang, Quan-Liang</creatorcontrib><creatorcontrib>Chen, Zhu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cai, Yeyu</au><au>Chang, Qian</au><au>Xiao, Enhua</au><au>Shang, Quan-Liang</au><au>Chen, Zhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2018-06-01</date><risdate>2018</risdate><volume>97</volume><issue>22</issue><spage>e10890</spage><epage>e10890</epage><pages>e10890-e10890</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>To compare the clinical efficacies and adverse reactions between transcatheter arterial chemoembolization (TACE), γ-ray 3-dimensional fractionated stereotactic conformal radiotherapy (FSCR), and TACE combined with FSCR for primary hepatocellular carcinoma.The study was approved by the Institutional Review Board, and informed consent was waived due to the retrospective study design. About 121 patients met the inclusion criteria and were included in this study, from March 2008 to January 2010, in the Second Xiangya Hospital. Forty-six patients underwent TACE alone, 36 patients underwent γ-knife alone, and 39 were treated by γ-knife combined with TACE. Short-term effects, overall survival rates, adverse reactions, and survival times were compared between the 3 treatment groups.Short-term effects were observed in 41.3% of the TACE group, 33.3% of the γ-knife group, and 64.1% of the TACE combined γ-knife group (P = .020). Overall survival rates at 6,12, 18, and 24 months were 50%, 34.8%, 28.3%, and 21.7% for the TACE group, 36.1%, 30.6%, 16.7%, and 11.1% for γ-knife group, and 84.6%, 71.8%, 61.5%, and 30.8% for TACE combined γ-knife group, respectively. The differences in the overall survival rates at 6, 12, and 18 months between the 3 groups were statistically significant (P = 0), but the overall survival rates at 24 months in the 3 groups were not significantly different (P = .117). The median survival time was 7 months for the TACE group, 3 months for the γ-knife group, and 20 months for the TACE combined γ-knife group (P = 0). There were statistically significant differences (P = .010) of leukopenia between the 3 groups, and no statistically significant differences of (P > .05) thrombocytopenia, anemia, nausea, vomiting, and liver function lesions.TACE combined with γ-knife for primary hepatocellular carcinoma is superior to TACE or γ-knife alone in short-term and long-term effects. This procedure is a mild, safe, and effective treatment for primary hepatocellular carcinoma.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>29851811</pmid><doi>10.1097/MD.0000000000010890</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2018-06, Vol.97 (22), p.e10890-e10890 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6392550 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - therapy Catheterization, Peripheral - methods Catheterization, Peripheral - mortality Chemoembolization, Therapeutic - methods Chemoembolization, Therapeutic - mortality Combined Modality Therapy Female Humans Liver Neoplasms - mortality Liver Neoplasms - therapy Male Middle Aged Observational Study Radiosurgery - methods Radiosurgery - mortality Radiotherapy, Conformal - methods Radiotherapy, Conformal - mortality Retrospective Studies Survival Rate Treatment Outcome Young Adult |
| title | Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T12%3A42%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transcatheter%20arterial%20chemoembolization%20(TACE)%20combined%20with%20%CE%B3-knife%20compared%20to%20TACE%20or%20%CE%B3-knife%20alone%20for%20hepatocellular%20carcinoma&rft.jtitle=Medicine%20(Baltimore)&rft.au=Cai,%20Yeyu&rft.date=2018-06-01&rft.volume=97&rft.issue=22&rft.spage=e10890&rft.epage=e10890&rft.pages=e10890-e10890&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000010890&rft_dat=%3Cpubmed_cross%3E29851811%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/29851811&rfr_iscdi=true |